C
Carrie Snyder
Researcher at Creighton University
Publications - 90
Citations - 6465
Carrie Snyder is an academic researcher from Creighton University. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 32, co-authored 89 publications receiving 5797 citations. Previous affiliations of Carrie Snyder include Georgetown University & University of Nebraska Medical Center.
Papers
More filters
Journal ArticleDOI
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Caryn Lerman,Steven A. Narod,Kevin A. Schulman,Chanita Hughes,Andres Gomez-Caminero,George E. Bonney,Karen Gold,Bruce J. Trock,David Main,Jane F. Lynch,Cecil Fulmore,Carrie Snyder,Stephen J. Lemon,Theresa Conway,Patricia N. Tonin,Gilbert M. Lenoir,Henry T. Lynch +16 more
TL;DR: Only a subset of HBOC family members are likely to request BRCA1 testing when available and rates of test use may be higher in persons of a higher socioeconomic status and those with more relatives affected with breast cancer.
Journal ArticleDOI
Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications
TL;DR: Because 40–60% of female patients will manifest endometrial cancer, tailored management is essential, and subtotal colectomy may be necessary, given the marked frequency of synchronous and metachronous CRC.
Journal ArticleDOI
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Timothy R. Rebbeck,Albert M. Levin,Andrea Eisen,Carrie Snyder,Patrice Watson,Lisa A. Cannon-Albright,Claudine Isaacs,O. I. Olopade,Judy Garber,Andrew K. Godwin,Mary B. Daly,Steven A. Narod,Susan L. Neuhausen,Henry T. Lynch,Barbara L. Weber +14 more
TL;DR: Bilateral prophylactic oophorectomy is associated with a reduced breast cancer risk in women who carry a BRCA1 mutation, and the likely mechanism is reduction of ovarian hormone exposure.
Journal ArticleDOI
Milestones of Lynch syndrome: 1895-2015
TL;DR: Over a century of discoveries that revolutionized the diagnosis and clinical management of Lynch syndrome are chronicle, beginning in 1895 with Warthin's observations of familial cancer clusters.
Journal ArticleDOI
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica,Carrie Snyder,Todd Maney,Anatole Ghazalpour,Daniel A. Holterman,Nianqing Xiao,Peggy Overberg,Inga Rose,Gargi D. Basu,Semir Vranic,Henry T. Lynch,Daniel D. Von Hoff,Omid Hamid +12 more
TL;DR: The utility of exploring the expression of two potentially targetable immune checkpoint proteins (PD-1/PD-L1) in a substantial proportion of solid tumors, including some aggressive subtypes that lack other targeted treatment modalities is demonstrated.